Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Radiotherapy concurrently with weekly cisplatin, followed by adjuvant chemotherapy, for N2-3 nasopharyngeal cancer: A multicenter trial of the Forum for Nuclear Cooperation in Asia
Authors: Tatsuya Ohno
Dang Huy Quoc Thinh
Shingo Kato
C. R Beena Devi
Ngo Thanh Tung
Kullathorn Thephamongkhol
Miriam Joy C Calaguas
Juying Zhou
Yaowalak Chansilpa
Nana Supriana
Dyah Erawati
Parvin Akhter Banu
Cho Chul Koo
Kunihiko Kobayashi
Takashi Nakano
Hirohiko Tsujii
Gunma University
Ho Chi Minh City Oncology Hospital
Saitama Medical University
Sarawak General Hospital
National Cancer Hospital
Mahidol University
St. Luke's Medical Center Quezon City
Soochow University
University of Indonesia, RSUPN Dr. Cipto Mangunkusumo
Dr. Soetomo Hospital
Delta Hospitals Limited
Korea Cancer Center Hospital
Gunma University Faculty of Medicine
National Institute of Radiological Sciences Chiba
Keywords: Environmental Science;Medicine;Physics and Astronomy
Issue Date: 1-May-2013
Citation: Journal of Radiation Research. Vol.54, No.3 (2013), 467-473
Abstract: The purpose of this study was to evaluate the efficacy and toxicity of radiotherapy concurrently with weekly cisplatin, followed by adjuvant chemotherapy, for the treatment of N2-3 nasopharyngeal cancer (NPC) in Asian countries, especially regions of South and Southeast Asian countries where NPC is endemic. Between 2005 and 2009, 121 patients with NPC (T1-4 N2-3 M0) were registered from Vietnam, Malaysia, Indonesia, Thailand, The Philippines, China and Bangladesh. Patients were treated with 2D radiotherapy concurrently with weekly cisplatin (30 mg/m 2), followed by adjuvant chemotherapy, consisting of cisplatin (80 mg/m2 on Day 1) and fluorouracil (800 mg/m2 on Days 1-5) for 3 cycles. Of the 121 patients, 56 patients (46%) required interruption of RT. The reasons for interruption of RT were acute non-hematological toxicities such as mucositis, pain and dermatitis in 35 patients, hematological toxicities in 11 patients, machine break-down in 3 patients, poor general condition in 2 patients, and others in 8 patients. Of the patients, 93% completed at least 4 cycles of weekly cisplatin during radiotherapy, and 82% completed at least 2 cycles of adjuvant chemotherapy. With a median follow-up time of 46 months for the surviving 77 patients, the 3-year locoregional control, distant metastasis-free survival and overall survival rates were 89%, 74% and 66%, respectively. No treatment-related deaths occurred. Grade 3-4 toxicities of mucositis, nausea/vomiting and leukopenia were observed in 34%, 4% and 4% of the patients, respectively. In conclusion, further improvement in survival and locoregional control is necessary, although our regimen showed acceptable toxicities. © 2012 The Author 2012.
ISSN: 13499157
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.